TORONTO CLINICAL NEUROPATHY SCORE AND MODIFIED TORONTO CLINICAL NEUROPATHY SCORE DIAGNOSTIC TESTS IN DISTAL DIABETIC SENSORIMOTOR POLYNEUROPATHY PATIENTS
DOI:
https://doi.org/10.61841/2wjh3k98Keywords:
diagnostic test, distal diabetic sensorimotor polyneuropathy, mTCN score, TCN scoreAbstract
Background: Distal diabetic sensorimotor polyneuropathy is a common complication that occurs in diabetes mellitus patients. Even though the number of diabetes mellitus patients has been increasing, the prevalence is still far from its actual numbers due to diagnostic and method criteria.
Objectives: We aimed to determine Toronto Clinical Neuropathy (TCN) and modified Toronto Clinical Neuropathy (mTCN) scores in distal diabetic sensorimotor polyneuropathy patients.
Methods: A cross-sectional study was carried out from October 29th, 2014, to June 1st, 2015, in 77 diabetes mellitus patients who visited an outpatient clinic. Polyneuropathy diagnosis was based on TCN and mTCN scores, with the gold standard of peroneal and/or sural nerve conduction velocity examination.
Results: The area under curve value of the TCN score was 84.5% (95% CI: 74.7%-94.3%). A TCN diagnostic score above 4 had sensitivity, specificity, and accuracy of 96%, 40%, and 82%, respectively. On the other hand, TCN diagnostic scores above 8 had sensitivity, specificity, and accuracy of 72%, 80%, and 74%, respectively. The AUC value of the mTCN score was 81.9% (95% CI: 71.8%-92.1%). mTCN diagnostic score above 8 had sensitivity, specificity, and accuracy of 63%, 75%, and 66%, respectively.
Conclusion: TNC scores above 4 could be used as a screening test, while scores above 8 could be used as a diagnostic test for distal DSP.
Downloads
References
[1] Maharani, A.I., Hasmono, D., Diansyah, M.N. Use of anti-dyslipidemia in type 2 diabetes mellitus. Indian Journal of Public Health Research and Development. 2019;10(8), pp. 1970-1976
[2] Wild S, Roglic G, Green A, Sicree R, and King H. Global Prevalence of Diabetes: Estimates for the year 2000 and Projections for 2030. Diabetes Care 2004; 27:1047-1053.
[3] Wulandari, I., Kusnanto, Nufus, S.H. Motivation affects self-efficacy greater than age, sex, and education in diabetic patients in the west coast area of Java island. Indian Journal of Public Health Research and Development. 2019; 10(8), pp. 2803-2807
[4] Romadhon, P.Z., Sutjahjo A., Novida, H., Prajitno, J.H., and Tjokroprawiro, A. HBA1C and plasma transforming growth factor beta 1 in type-2 diabetes mellitus patients. New Armenian Medical Journal. 2019;13(1), pp. 69-73
[5] Katulanda P, Ranasinghe P, Jayawardena R, Constantine GR, Sheriff MHR, and Matthews DR. The prevalence, patterns, and predictors of diabetic peripheral neuropathy in a developing country. Diabetology & Metabolic Syndrome 2012; 21:1-8.
[6] Shakher J. and Stevens MJ. Diabetes, Metabolic Syndrome, and Obesity: Targets and Therapy. The Management of Diabetic Polyneuropathies 2011; 4:289-305.
[7] Callaghan BC, Cheng HT, Stables CL, Smith AL, and Feldman EL. Diabetic Neuropahy: Clinical Manifestations and Current Treatments. Lancet Neurol 2012; 11:521-534.
[8] England JD, Gronseth GS, Franklin G, Miller RG, Asbury AK, Carter GT, and al. Distal symmetric polyneuropathy: A definition for clinical research: Report of the American Academy of Neurology, the American Association of Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology 2005; 64:199–207.
[9] Bril V and Perkins BA. Original Article: Validation of the Toronto Clinical Scoring System for Diabetic Polyneuropathy. Diabetes Care 2002; 25:2048-2052.
[10] Liu F, Mao JP, and Yan X. Toronto Clinical Scoring System in diabetic peripheral neuropathy. Journal of Central South University, Medical Science 2008; 33:1137-1141.
[11] Bril V, Tomioka S, Buchanan RA, and Perkins BA. Original Article: Complications Reliability and Validity of the Modified Toronto Clinical Neuropathy Score in Diabetic Sensorimotor Polyneuropathy. Diabetic Medicine 2009; 26:240-246.
[12] Dutta A, Naorem S, Singh P, and Wangjam K. Prevalence of peripheral neuropathy in newly diagnosed type 2 diabetes. Int J Diab Dev 2005; 25:30-32.
[13] Young MJ, Boulton AJM, Macleod AF, Williams DRR, and Sonksen PH. A multicenter study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population. Diabetologia 1993; 36:150-154.
[14] Tesfaye S, Chaturvedi N, Eaton S, Ward JD, Manes C, Tirgoviste CI, Witte DR, and Fuller JH. Vascular risk factors and diabetic neuropathy. N Eng J Med 2005; 52:341-350.
[15] Al SK, Althwabia I, Khaled MB, and Haddad F. Prevalence of peripheral neuropathy among patients with diabetes mellitus at King Hussein Hospital, Amman, Jordan. Rawal Medical Journal 2013; 38:92-96.
[16] Luaibi, H.M., Alfarhani, B.F., Hammza, R.A. Comparative assessment of catechin and gallic acid content in different brands of black and green tea (2018) International Journal of Pharmaceutical Research, 10 (4), pp. 585-589. https://www.scopus.com/inward/record.uri?eid=2-s2.0-
85062401505&doi=10.31838%2fijpr%2f2018.10.04.102&partnerID=40&md5=9fdbb15176b3353b1e03813e5be5f3fb
[17] Debarshi kar mahapatra, Vivek Asati, and Sanjay Kumar Bharti (2019) recent therapeutic progress of chalcone scaffold-bearing compounds as prospective anti-gout candidates. Journal of Critical Reviews, 6 (1), 1-5. doi:10.22159/jcr.2019v6i1.31760
[18] Shukla SS, Saraf S, Saraf S. "Fundamental Aspect and Basic Concept of Siddha Medicines." Systematic Reviews in Pharmacy 2.1 (2011), 48-54. Print. doi:10.4103/0975-8453.83439
Downloads
Published
Issue
Section
License
Copyright (c) 2020 AUTHOR
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
